Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Enliven Therapeutics, Inc. completed a disposition involving Cardurion Pharmaceuticals, Inc. for $34,750,000 upfront cash payment (closed 2022-11-10).
- Action
- disposition
- Counterparty
- Cardurion Pharmaceuticals, Inc.
- Consideration
- $34,750,000 upfront cash payment
- Closing
- 2022-11-10
Exact text from the filing
On November 10, 2022, the Asset Sale was consummated and, in accordance with the Asset Purchase Agreement, Cardurion paid to Imara an upfront cash payment of $34,750,000 upon closing of the Asset Sale.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Enliven Therapeutics, Inc. shareholders approved Approval of the sale of assets related to the PDE9 program to Cardurion at the 2022-11-09 meeting.
- Outcome
- passed
- Meeting
- 2022-11-09
Exact text from the filing
Proposal No. 1: To approve the sale by the Company to Cardurion of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program, pursuant to the terms of the Asset Purchase Agreement, for an upfront cash payment of $34,750,000 upon closing of the Asset Sale (in addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet), a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms and conditions of the Asset Purchase Agreement (the “ Asset Sale Proposal ”). This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain Broker Non-Votes 18,366,825 11,907 47,876
View on SEC.gov